The DOI matches its Crossref record; 187 of the 187 references it cites were found in a registry or an index.
Diabetes and cancer
Open accessAbstract
Diabetes and cancer are two heterogeneous, multifactorial, severe, and chronic diseases. Because of their frequency, reciprocal influences - even minor influences - may have a major impact. Epidemiological studies clearly indicate that the risk of several types of cancer (including pancreas, liver, breast, colorectal, urinary tract, and female reproductive organs) is increased in diabetic patients. Mortality is also moderately increased. Several confounding factors, having general or site-specific relevance, make it difficult to accurately assess cancer risk in diabetic patients. These factors include diabetes duration, varying levels of metabolic control, different drugs used for therapy, and the possible presence of chronic complications. Hyperinsulinemia most likely favors cancer in diabetic patients as insulin is a growth factor with pre-eminent metabolic but also mitogenic effects, and its action in malignant cells is favored by mechanisms acting at both the receptor and post-receptor level. Obesity, hyperglycemia, and increased oxidative stress may also contribute to increased cancer risk in diabetes. While anti-diabetic drugs have a minor influence on cancer risk (except perhaps the biguanide metformin that apparently reduces the risk), drugs used to treat cancer may either cause diabetes or worsen a pre-existing diabetes. In addition to the well-known diabetogenic effect of glucocorticoids and anti-androgens, an increasing number of targeted anti-cancer molecules may interfere with glucose metabolism acting at different levels on the signaling substrates shared by IGF-I and insulin receptors. In conclusion, diabetes and cancer have a complex relationship that requires more clinical attention and better-designed studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Diabetes is associated with reduced risk of prostate cancer.”
From Diabetes and Cancer (2010) · cites this paper as [6]
In the citing paper
“Diabetes (primarily type 2) is associated with increased risk for some cancers (liver, pancreas, endometrium, colon and rectum, breast, bladder).”
From Diabetes and Cancer (2010) · cites this paper as [6]
In the citing paper
“Epidemiologic evidence suggests that people with diabetes are at significantly higher risk for many forms of cancer.”
From Diabetes and Cancer (2010) · cites this paper as [6]
In the citing paper
“For some other cancer sites there appears to be no association or the evidence is inconclusive.”
From Diabetes and Cancer (2010) · cites this paper as [6]
In the citing paper
“Other cancers (e.g., lung) do not appear to be associated with an increased risk in diabetes, and the evidence for others (e.g., kidney, non-Hodgkin lymphoma) is inconclusive.”
From Diabetes and Cancer (2010) · cites this paper as [6]
In the citing paper
“The relative risks imparted by diabetes are greatest (about twofold or higher) for cancers of the liver, pancreas, and endometrium, and lesser (about 1.2–1.5 fold) for cancers of the colon and rectum, breast, and bladder.”
From Diabetes and Cancer (2010) · cites this paper as [6]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Warburg, O. (1956) · Science · doi:10.1126/science.123.3191.309 · Cited by 13,425
Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. Adults
Calle, E. E., Rodriguez, C., Walker-Thurmond, K., & Thun, M. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021423 · Cited by 7,696
JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM
Hoskins, R. G. (1953) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-13-4-473 · Cited by 3,780
THE JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
(1911) · JAMA · doi:10.1001/jama.1911.04260070032017 · Cited by 3,355
Harris, M. I., Flegal, K. M., Cowie, C. C., Eberhardt, M. S., Goldstein, D. E., Little, R. R., Wiedmeyer, H.-M., & Byrd-Holt, D. D. (1998) · Diabetes Care · doi:10.2337/diacare.21.4.518 · Cited by 2,703
Metformin and reduced risk of cancer in diabetic patients
Evans, J. M. M., Donnelly, L. A., Emslie-Smith, A. M., Alessi, D. R., & Morris, A. D. (2005) · BMJ · doi:10.1136/bmj.38415.708634.f7 · Cited by 2,388
Giovannucci, E., Harlan, D. M., Archer, M. C., Bergenstal, R. M., Gapstur, S. M., Habel, L. A., Pollak, M., Regensteiner, J. G., & Yee, D. (2010) · Diabetes Care · doi:10.2337/dc10-0666 · Cited by 2,366
The American Journal of Gastroenterology
(2003) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2003.80003397.x · Cited by 2,202
Insulin and insulin-like growth factor signalling in neoplasia
Pollak, M. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2536 · Cited by 2,059
Archives of Biochemistry and Biophysics
Carter, H. E., Bhattacharyya, P., Weidman, K. R., & Fraenkel, G. (2009) · Nutrition Reviews · doi:10.1111/j.1753-4887.1981.tb06727.x · Cited by 1,895
Flagged first, then by citations
Research works printed but not linked: 1
- Lindblad P Adami HO 2002 Kidney cancer. In Textbook of Cancer Epidemiology, pp 467–485 Eds HunterDAdamiHOTrichopoulosD. New York: Oxford University Press.
Cited by
Sorted by citations
Items 501–600 of 1,000
Metformin: risk-benefit profile with a focus on cancer
Provinciali, N., Lazzeroni, M., Cazzaniga, M., Gorlero, F., Dunn, B. K., & DeCensi, A. (2015) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2015.1084289 · Cited by 21
Diabetes mellitus, medications for type 2 diabetes mellitus, and cancer risk
Vecchia, C. L. (2011) · Metabolism · doi:10.1016/j.metabol.2011.03.011 · Cited by 20
de Jong, R. G. P. J., Burden, A. M., de Kort, S., van Herk‐Sukel, M. P. P., Vissers, P. A. J., Janssen, P. K. C., Haak, H. R., Masclee, A., de Vries, F., & Janssen-Heijnen, M. L. G. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.03.039 · Cited by 20
Mansor, R., Holly, J. M. P., Barker, R. M., Biernacka, K. M., Zielinska, H., Koupparis, A. J., Rowe, E., Oxley, J., Sewell, A., Martin, R. M., et al. (2020) · Oncotarget · doi:10.18632/oncotarget.27650 · Cited by 20
Mascolo, E., Liguori, F., Merigliano, C., Schiano, L., Gnocchini, E., Pilesi, E., Volonté, C., di Salvo, M. L., Contestabile, R., Tramonti, A., et al. (2022) · Journal of Cellular Physiology · doi:10.1002/jcp.30812 · Cited by 20
Chodick, G., & Zucker, I. (2011) · Women s Health · doi:10.2217/whe.11.4 · Cited by 20
Insulin Therapy and Cancer in Type 2 Diabetes
Mannucci, E. (2012) · ISRN Endocrinology · doi:10.5402/2012/240634 · Cited by 21
Non-small cell lung cancer cell survival crucially depends on functional insulin receptors
Frisch, C. M., Zimmermann, K., Zilleßen, P., Pfeifer, A., Racké, K., & Mayer, P. E. (2015) · Endocrine Related Cancer · doi:10.1530/erc-14-0581 · Cited by 19
Insulin induces an EMT‐like process in mammary epithelial cells MCF10A
Rodriguez‐Monterrosas, C., Díaz‐Aragon, R., Leal‐Orta, E., Cortés‐Reynosa, P., & Salazar, E. P. (2017) · Journal of Cellular Biochemistry · doi:10.1002/jcb.26582 · Cited by 20
Amadou, A., Freisling, H., Jenab, M., Tsilidis, K. K., Trichopoulou, A., Boffetta, P., Guelpen, B. R. V., Mokoroa, O., Wilsgaard, T., Kee, F., et al. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01347-4 · Cited by 20
Shahbazi, R., Cheraghpour, M., Homayounfar, R., Nazari, M., Nasrollahzadeh, J., & Davoodi, S. H. (2018) · Journal of Cancer Research and Therapeutics · doi:10.4103/0973-1482.157323 · Cited by 20
An integrated care pathway for cancer patients with diabetes: A proposal from the Italian experience
Gallo, M., Clemente, G., Corsi, D. C., Michelini, M., SURACI, C., Farci, D., Ponziani, M. C., Candido, R., Russo, A. D., Musacchio, N., et al. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.04.036 · Cited by 19
“[1] Vigneri P, Frasca F, Sciacca L, Pandini G, Vigneri R.”
BackgroundKim, Y.-S., Choi, E.-A., Lee, J., Kim, Y., You, H., Han, Y.-E., Kim, H.-S., Bae, Y., Kang, H., & Kim, J. (2020) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2020.05.010 · Cited by 18
Type 2 diabetes and cancer: problems and suggestions for best patient management
Milluzzo, A., Vigneri, P. G., Martorana, F., Vigneri, R., & Sciacca, L. (2020) · Exploration of Medicine · doi:10.37349/emed.2020.00013 · Cited by 19
“Conversely, patients in androgen deprivation therapy for prostate cancer had a more pronounced HbA1c worsening, remarking the detrimental effect of gonadotropin releasing hormone (GnRH) agonists, steroidal (cyproterone acetate) and nonsteroidal anti-androgens (flutamide, bicalutamide, and nilutamide) on body weight, f…”
BackgroundZhan, Z., Liu, L., Cheng, M., Gao, Y., & Zhou, W. (2022) · Journal of Immunology Research · doi:10.1155/2022/2651790 · Cited by 20
Zhang, T., Chen, C., Breslin, M. B., Song, K., & Lan, M. S. (2014) · Cellular Signalling · doi:10.1016/j.cellsig.2013.12.014 · Cited by 19
de Heer, J., & Göke, B. (2014) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2014.955013 · Cited by 19
Insulin Analogs and Cancer: A Note of Caution
Janssen, J. A. M. J. L., & Varewijck, A. J. (2014) · Frontiers in Endocrinology · doi:10.3389/fendo.2014.00079 · Cited by 19
Shen, T., Chung, W., Lin, C., Wei, C., Chen, C., Chen, H.-J., Tu, C., Hsia, T., Shih, C., Hsu, W., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0098290 · Cited by 19
Hasan, M., & Mohieldein, A. (2015) · PubMed Central · Cited by 19
Changes in the prevalence of comorbidity in the Australian population with cancer, 2007–2014
Ng, H. S., Koczwara, B., Roder, D. M., & Vitry, A. I. (2018) · Cancer Epidemiology · doi:10.1016/j.canep.2018.03.010 · Cited by 19
Anti-Diabetic Drugs: Cure or Risk Factors for Cancer?
Laskar, J., Bhattacharjee, K., Sengupta, M., & Choudhury, Y. (2018) · Pathology & Oncology Research · doi:10.1007/s12253-018-0402-z · Cited by 20
Melatonin May Increase Anticancer Potential of Pleiotropic Drugs
Bojková, B., Kubatka, P., Qaradakhi, T., Zulli, A., & Kajo, K. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19123910 · Cited by 21
“Diabetes incidence rises worldwide and type 2 diabetic patients constitute up to 90% of all cases [237].”
Sun, Y. X., Zhu, M., Zhao, H., Ni, X., Chang, R., Su, J., Huang, H., Cui, S., Wang, X., Yuan, J., et al. (2020) · BioMed Research International · doi:10.1155/2020/1751989 · Cited by 19
“Specifically, a meta-analysis suggested that diabetes increases the risk of liver and pancreatic cancer [3], and a majority of studies have also shown that diabetes is an independent risk factor for the development and progression of HCC [4, 5].”
BackgroundComparison of NN and LR classifiers in the context of screening native American elders with diabetes
Upadhyaya, S., Farahmand, K., & Baker‐Demaray, T. (2013) · Expert Systems with Applications · doi:10.1016/j.eswa.2013.05.012 · Cited by 20
Klopfleisch, R., Hvid, H., Klose, P., da Costa, A., & Gruber, A. D. (2010) · Veterinary and Comparative Oncology · doi:10.1111/j.1476-5829.2009.00232.x · Cited by 19
Diabetes and risk of bladder cancer among postmenopausal women in the Iowa women’s health study
Prizment, A. E., Anderson, K. E., Yuan, J., & Folsom, A. R. (2013) · Cancer Causes & Control · doi:10.1007/s10552-012-0143-3 · Cited by 19
Cancer risks from diabetes therapies: Evaluating the evidence
Li, C., & Kong, D. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.05.006 · Cited by 18
Ambrosio, M. R., Mosca, G., Migliaccio, T., Liguoro, D., Nele, G., Schönauer, F., D’Andrea, F., Liotti, F., Prevete, N., Melillo, R. M., et al. (2022) · Cancers · doi:10.3390/cancers14215421 · Cited by 18
Metformin derivatives – Researchers’ friends or foes?
Torunoglu, S. T., Zajda, A., Tampio, J., Markowicz-Piasecka, M., & Huttunen, K. M. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115743 · Cited by 22
Implications of breast cancer with diabetes mellitus on patient outcomes and care
Karlin, N. J., Dueck, A. C., Reddy, S. K. N., Verona, P. M., & Cook, C. B. (2014) · Diabetes Management · doi:10.2217/dmt.14.39 · Cited by 18
Statin Use and Cancer Incidence in Patients with Type 2 Diabetes Mellitus: A Network Meta-Analysis
Hu, Y., Hu, E.-D., & Fu, R. (2018) · Gastroenterology Research and Practice · doi:10.1155/2018/8620682 · Cited by 17
Choi, Y. J., Kim, D. J., & Shin, S. (2019) · Cancer Management and Research · doi:10.2147/cmar.s215107 · Cited by 20
Distinct function of the head region of human pancreas in the pathogenesis of diabetes
Savari, O., Zielinski, M. C., Wang, X., Misawa, R., Millis, J. M., Witkowski, P., & Hara, M. (2013) · Islets · doi:10.4161/isl.26432 · Cited by 18
Vaira, S., Friday, E., Scott, K., Conrad, S. A., & Turturro, F. (2011) · Journal of Cellular Physiology · doi:10.1002/jcp.22757 · Cited by 18
Yamagishi, S., Sotokawauchi, A., & Matsui, T. (2019) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557519666190311140737 · Cited by 17
He, S., Wang, J., Shen, X., Qian, X., An, Y., Gong, Q., Zhang, B., Chen, B., Zhang, L., Chen, X., et al. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-01758-x · Cited by 17
Khajah, M. A., Khushaish, S., & Luqmani, Y. A. (2022) · PLoS ONE · doi:10.1371/journal.pone.0272449 · Cited by 17
Ennis, C. S., Llévenes, P., Qiu, Y., Dries, R., & Denis, G. V. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1044670 · Cited by 20
“For example, insulin-independent hyperglycemia increases the size of liver tumors and reduces apoptosis in a tumor-prone animal model, whereas in T1D in vivo models tumor growth is reduced by insulin (44, 45).”
BackgroundThe putative metabolic role of d -chiro inositol phosphoglycan in human pregnancy and preeclampsia
Scioscia, M., Nigro, M., & Montagnani, M. (2013) · Journal of Reproductive Immunology · doi:10.1016/j.jri.2013.05.006 · Cited by 17
Rothe, D., Paterson, I., Cox-Kennett, N., Gyenes, G. T., & Pituskin, E. (2017) · Current Epidemiology Reports · doi:10.1007/s40471-017-0117-9 · Cited by 17
Short-term adverse effects of anticancer drugs in patients with type 2 diabetes
Milluzzo, A., Tumminia, A., Vella, V., Gianì, F., Manzella, L., Frittitta, L., Belfiore, A., Vigneri, R., & Sciacca, L. (2019) · Journal of Chemotherapy · doi:10.1080/1120009x.2019.1572297 · Cited by 17
Khodaei, F., Hosseini, S. M., Omidi, M., Hosseini, S. F., & Rezaei, M. (2020) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.22662 · Cited by 16
Nutritional control of postembryonic development progression and arrest in Caenorhabditis elegans
Mata‐Cabana, A., Pérez-Nieto, C., & Olmedo, M. (2020) · Advances in genetics · doi:10.1016/bs.adgen.2020.11.002 · Cited by 16
Amin, A. M. (2021) · Lifestyle Medicine · doi:10.1002/lim2.25 · Cited by 18
Arif, J. M., Alsaif, A., Al-Karrawi, M., & Al‐Sagair, O. A. (2011) · PubMed · Cited by 17
Berstein, L. M., Iyevleva, A. G., Vasilyev, D., Евгеньевна, П. Т., & Имянитов, Е. Н. (2013) · Cell Cycle · doi:10.4161/cc.26868 · Cited by 18
Yang, W.-S., Chen, P., Lin, H., Su, T., Hsu, H., Chen, M.-F., Lee, Y., & Chien, K. (2017) · Acta Diabetologica · doi:10.1007/s00592-017-0966-1 · Cited by 17
Sedentary Behaviour and Cancer
Lynch, B. M., Mahmood, S., & Boyle, T. (2017) · Springer series on epidemiology and public health · doi:10.1007/978-3-319-61552-3_10 · Cited by 17
Park, D. (2019) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b19-00474 · Cited by 17
Perrier, Q., Jambon-Barbara, C., Kessler, L., Villard, O., Buron, F., Guerci, B., Borot, S., Roustit, M., Berishvilli, E., Rakotoarisoa, L., et al. (2025) · Diabetes Care · doi:10.2337/dc25-0059 · Cited by 15
Yang, H., Wu, C.-Y., Powell, J. D., & Lu, K. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21114030 · Cited by 17
“For instance, a meta-analysis study sums up the epidemiological evidence, indicating that the incidences of various cancers, including pancreas, liver, breast, colorectal, urinary tract and female reproductive organs, are increased in diabetic patients [69].”
BackgroundExploring the Relationship between Obesity, Metabolic Syndrome and Neuroendocrine Neoplasms
Lan, X., Fazio, N., & Abdel-Rahman, O. M. (2022) · Metabolites · doi:10.3390/metabo12111150 · Cited by 15
Swerdlow, A. J., Jones, M. E., Slater, S. D., Burden, A. C., Botha, J. L., Waugh, N. R., Morris, A. D., Gatling, W., Gillespie, K. M., Patterson, C., et al. (2023) · International Journal of Cancer · doi:10.1002/ijc.34548 · Cited by 15
Dapagliflozin in type 2 diabetes: effectiveness across the spectrum of disease and over time
Parikh, S. J., Wilding, J. P. H., Jabbour, S. A., & Hardy, E. (2014) · International Journal of Clinical Practice · doi:10.1111/ijcp.12531 · Cited by 16
Gu, Y., Hou, X., Zheng, Y., Wang, C., Zhang, L., Li, J., Huang, Z., Han, M., Bao, Y., Zhong, W., et al. (2016) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph13060559 · Cited by 16
Lin, C., Cai, X., Yang, W., Lv, F., Nie, L., & Ji, L. (2020) · Endocrine · doi:10.1007/s12020-020-02376-4 · Cited by 16
Biologic Evaluation of Diabetes and Local Recurrence in Non-Small Cell Lung Cancer
Yang, X., Liu, Y.-J., Mani, H., Olson, J., Clawson, G. A., Caruso, C., Bruggeman, R., Varlotto, J. M., Zander, D. S., & Rassaei, N. (2016) · Pathology & Oncology Research · doi:10.1007/s12253-016-0086-1 · Cited by 16
Biomarkers of the Metabolic Syndrome and Breast Cancer Prognosis
Zhu, Q., Xu, W., & Tao, M. (2010) · Cancers · doi:10.3390/cancers2020721 · Cited by 16
Jabbour, S. A., Whaley, J. M., Tirmenstein, M. A., Poucher, S. M., Reilly, T. P., Boulton, D. W., Saye, J. A., List, J. F., & Parikh, S. J. (2012) · Postgraduate Medicine · doi:10.3810/pgm.2012.07.2569 · Cited by 15
Íñiguez-Luna, M. I., Cadena-Íñiguez, J., Soto‐Hernández, M., Flores, F. J. M., Cortés-Cruz, M., Watanabe, K. N., Machida-Hirano, R., & Cadena-Zamudio, J. D. (2021) · Scientific Reports · doi:10.1038/s41598-021-85676-7 · Cited by 15
Impact of diabetes on the increased risk of hepatic cancer: An updated review of biological aspects
Das, B. K., & Gadad, P. C. (2021) · Diabetes Epidemiology and Management · doi:10.1016/j.deman.2021.100025 · Cited by 15
Harlid, S., Guelpen, B. R. V., Qu, C., Gylling, B., Aglago, E. K., Amitay, E. L., Brenner, H., Buchanan, D. D., Campbell, P. T., Cao, Y., et al. (2022) · International Journal of Cancer · doi:10.1002/ijc.34015 · Cited by 15
Jin, L., Zheng, D., Mo, D., Guan, Y., Wen, J., Zhang, X., & Chen, C. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.829009 · Cited by 15
van den Brandt, P. A. (2024) · European Journal of Epidemiology · doi:10.1007/s10654-024-01100-0 · Cited by 15
World Congress on Insulin Resistance, Diabetes, and Cardiovascular Disease
Bloomgarden, Z. T. (2011) · Diabetes Care · doi:10.2337/dc11-1306 · Cited by 15
Holden, S. E. (2016) · Endocrine development · doi:10.1159/000439410 · Cited by 15
Saito, Y., Noto, H., Takahashi, O., & Kobayashi, D. (2019) · The Cancer Journal · doi:10.1097/ppo.0000000000000387 · Cited by 15
Isoform- and Paralog-Switching in IR-Signaling: When Diabetes Opens the Gates to Cancer
Scalia, P., Giordano, A., Martini, C., & Williams, S. J. (2020) · Biomolecules · doi:10.3390/biom10121617 · Cited by 15
“Under these conditions, the chronically increased insulin levels associate with increased cancer risk [9,10] and to parallel increase levels in IR and Insulin-like Growth factor I (IGF1R) [11].”
BackgroundClinical Significance of Acute Kidney Injury in Lung Cancer Patients
Cho, S., Kang, E., Kim, J. E., Kang, U., Kang, H. G., Park, M., Kim, K., Kim, D. K., Joo, K. W., Kim, Y. S., et al. (2021) · Cancer Research and Treatment · doi:10.4143/crt.2020.1010 · Cited by 15
Xiu, W., Huang, Y., Li, Y., Yu, M., & Gong, Y. (2021) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000001133 · Cited by 15
Metformin and Cancer in Type 2 Diabetes
Park, H. K. (2013) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2013.37.2.113 · Cited by 16
Yokoyama, N. N., Denmon, A. P., Uchio, E., Jordan, M. L., Mercola, D., & Zi, X. (2015) · Current Pharmacology Reports · doi:10.1007/s40495-015-0039-5 · Cited by 15
Onitilo, A. A., Donald, M., Stankowski, R. V., Engel, J. M., Williams, G. M., & Doi, S. A. R. (2013) · Clinical Medicine & Research · doi:10.3121/cmr.2013.1156 · Cited by 15
Twarock, S., Reichert, C., Peters, U., Gorski, D. J., Roeck, K., & Fischer, J. W. (2017) · International Journal of Cancer · doi:10.1002/ijc.30776 · Cited by 15
Metformin and Breast Cancer Risk
Gandini, S., Guerrieri‐Gonzaga, A., Puntoni, M., & DeCensi, A. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.3596 · Cited by 15
Aktar, B. S. K., Sıcak, Y., Bakırdöven, A., Tatar, G., Yılmaz, Ö., Karaküçük‐İyidoğan, A., Taşdemir, D., Sağlam, E., & Oruç‐Emre, E. E. (2025) · ACS Omega · doi:10.1021/acsomega.4c10095 · Cited by 14
Chikermane, S. G., Sharma, M., Abughosh, S., Aparasu, R. R., Trivedi, M. V., & Johnson, M. L. (2022) · Breast Cancer Research and Treatment · doi:10.1007/s10549-022-06706-0 · Cited by 14
Bladder cancer with pioglitazone: A case–control study
Malhotra, B., Hiteshi, P., Khalkho, P., Malik, R., Bhadada, S. K., Bhansali, A. K., Shafiq, N., Malhotra, S., Kumar, N., Rajput, R., et al. (2022) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2022.102637 · Cited by 14
Association of metformin, aspirin, and cancer incidence with mortality risk in adults with diabetes
Orchard, S. G., Lockery, J. E., Broder, J. C., Ernst, M. E., Espinoza, S. E., Gibbs, P., Wolfe, R. S., Polekhina, G., Zoungas, S., Loomans-Kropp, H. A., et al. (2023) · JNCI Cancer Spectrum · doi:10.1093/jncics/pkad017 · Cited by 15
Interlinking of diabetes mellitus and cancer: An overview
Ahmad, I., Suhail, M., Ahmad, A., Alhosin, M., & Tabrez, S. S. M. (2023) · Cell Biochemistry and Function · doi:10.1002/cbf.3802 · Cited by 14
“accompanied by hyperglycemia, inhibits tumor growth opposing the hypothesis that hyperglycemia promotes tumor growth, especially shortage of insulin shortage.(50) The cancer risk in diabetic patients is unaffected by the better glycemic control.”
BackgroundMicroRNA-497 regulates cell proliferation in hepatocellular carcinoma
Ding, W., Ni, Q., Lu, Y., KONG, L.-L., YU, J.-J., Tan, L., & KONG, L.-B. (2015) · Oncology Letters · doi:10.3892/ol.2015.3981 · Cited by 14
Zhang, D., Hou, W., Liu, F., Yin, J., Lu, W., Li, M., Zheng, T., Lu, F., Bao, Y., & Jia, W. (2014) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2014.0176 · Cited by 14
Impact of Diabetes Mellitus on Head and Neck Cancer Patients Undergoing Concurrent Chemoradiotherapy
Kuo, H.-C., Chang, P., & Wang, C. (2020) · Scientific Reports · doi:10.1038/s41598-020-64844-1 · Cited by 14
Thonsri, U., Wongkham, S., Wongkham, C., Hino, S., Nakao, M., Roytrakul, S., Koga, T., & Seubwai, W. (2020) · Cancer Science · doi:10.1111/cas.14719 · Cited by 13
Hisanaga, K., Uchino, H., Kakisu, N., Miyagi, M., Yoshikawa, F., Sato, G. E., Isobe, K., Kishi, K., Homma, S. A., & Hirose, T. (2021) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s289446 · Cited by 14
Insulin-Degrading Enzyme, an Under-Estimated Potential Target to Treat Cancer?
Lesire, L., Leroux, F., Deprez-Poulain, R. F., & Deprez, B. P. (2022) · Cells · doi:10.3390/cells11071228 · Cited by 14
AGE-breaker ALT711 reverses glycation-mediated cancer cell migration
Rowe, M. M., Wang, W., Taufalele, P., & Reinhart‐King, C. A. (2022) · Soft Matter · doi:10.1039/d2sm00004k · Cited by 14
Proteinuria predicts 10-year cancer-related mortality in patients with type 2 diabetes
Yu, T., Li, H., Jiang, Y., Chang, T., Wei, J., & Chuang, L. (2013) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2012.11.007 · Cited by 14
Diabetes Mellitus and HbA1c Levels Associated with High Grade Prostate Cancer
Özbek, E., Ötünçtemur, A., Dursun, M., Şahin, S., Beşiroğlu, H., Köklü, İ., Erkoç, M., Danış, E., & Bozkurt, M. (2014) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2014.15.6.2555 · Cited by 14
Hammer, M. J., Aouizerat, B. E., Schmidt, B. L., Cartwright, F., Wright, F., & Miaskowski, C. A. (2015) · Oncology nursing forum · doi:10.1188/15.onf.581-590 · Cited by 14
Diabetes-associated dysregulated cytokines and cancer
Wu, Y., Dong, Y., Liu, Y., & Vadgama, J. V. (2016) · Integrative Cancer Science and Therapeutics · doi:10.15761/icst.1000173 · Cited by 13
Albai, O., Frandeș, M., Timar, B., Paun, D., Roman, D., & Timar, R. Z. (2020) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s243263 · Cited by 15
Choi, Y. J., Bak, K., Yeo, Y., Choi, Y., & Shin, S. (2021) · Pharmaceuticals · doi:10.3390/ph14090925 · Cited by 14
Sahinoz, M., Luther, J. M., Mashayekhi, M., Jung, D. K., Ikizler, T. A., & Engelhardt, B. G. (2022) · Blood Advances · doi:10.1182/bloodadvances.2021006241 · Cited by 14
Chen, C., Chiu, W., Tseng, Y., Lin, C.-M., Yang, H., Yang, Y., & Chen, P. (2022) · Phytomedicine · doi:10.1016/j.phymed.2022.154023 · Cited by 13
Advancements in the study of glucose metabolism in relation to tumor progression and treatment
Zhao, M., Chen, Y., & Yang, L. (2024) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2024.08.001 · Cited by 13
Insights Into Heart-Tumor Interactions in Heart Failure
Caller, T., Moore, K. J., Lehmann, L., Wu, S. M., & Leor, J. (2025) · Circulation Research · doi:10.1161/circresaha.124.325490 · Cited by 15
Growth Modulation of Diabetic Factors and Antidiabetic Drugs on Prostate Cancer Cell Lines
Chien, S.-W. (2016) · The Chinese Journal of Physiology · doi:10.4077/cjp.2016.bae368 · Cited by 13
Zhang, F., Chen, H., Du, J., Wang, B., & Yang, L. (2018) · Medical Science Monitor · doi:10.12659/msm.909745 · Cited by 13
Retracted
Metadata
- Authors
- Vigneri, P., Frasca, F., Sciacca, L., Pandini, G., & Vigneri, R.
- Affiliations
- Section of General Pathology 1
- University of Catania (IT)
- Corresponding author
- Vigneri, Paolo
- Venue
- Endocrine Related Cancer
- Publisher
- Bioscientifica
- Published
- 2009-12-01
- Volume
- 16
- Issue
- 4
- Pages
- 1103-1123
- ISSN
- 1351-0088 (ISSN-L)
- 1479-6821
- OpenAlex
- W2163691729
- Cited by
- 1,009
- References
- 183
- Citations by year
- 2026: 20 · 2025: 43 · 2024: 54 · 2023: 49 · 2022: 49 · 2021: 46 · 2020: 50 · 2019: 57 · 2018: 60 · 2017: 75 · 2016: 59 · 2015: 68 · 2014: 85 · 2013: 97 · 2012: 80
- FWCI
- 5.00
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Endocrine Related Cancer (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Associazione Italiana per la Ricerca sul Cancro
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Health Sciences › Medicine › Oncology › Cancer Risks and Factors
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
- Keywords
- diabetes mellitus, cancer risk, hyperinsulinemia, insulin-like growth factor I, insulin receptor, metformin, antidiabetic drugs, glucocorticoids, androgen receptor antagonists, obesity, hyperglycemia, oxidative stress, pancreatic cancer, liver cancer, breast cancer, colorectal cancer, cancer mortality, confounding factors
- MeSH terms
- Humans, Neoplasms, Risk Factors, Survival Rate, Diabetes Complications
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
